Portage Biotech Inc. - Common Stock (PRTG)

The company is preparing to launch a first-in-human clinical trial for PORT-7 and is simultaneously advancing dose escalation for PORT-6, a selective A2A receptor inhibitor.

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Portage Biotech stock jumped after new PORT-7 data showed enhanced immune response and plans advanced for combined A2A and A2B receptor blockade.

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Which stocks have an unusual volume on Friday?

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.